Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Cash from Financing Activities of $2.7 million for Q1 2026, up 476.07% year-over-year from $468000.0 in Q1 2025, and down 33.76% quarter-over-quarter from $4.1 million in Q4 2025.
Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Cash from Financing Activities for 7 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 476.07% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $7.0 million (up 49.76% YoY), while the FY2025 annual figure was $4.8 million, down 71.17% from the prior year.
- Cash from Financing Activities fell to $2.7 million in Q1 2026 per CRBU's latest filing, from $4.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $135.1 million in Q3 2023 and bottomed at -$43000.0 in Q4 2023.
- Historically, Cash from Financing Activities has averaged $10.6 million across 5 years, with a median of $654000.0 in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 20561.77% in 2023 and fell as far as 133.86% in 2023.
- Caribou Biosciences' Cash from Financing Activities stood at $127000.0 in 2022, then sank by 133.86% to -$43000.0 in 2023, then soared by 9083.72% to $3.9 million in 2024, then advanced by 5.36% to $4.1 million in 2025, then sank by 33.76% to $2.7 million in 2026.
- Business Quant data shows CRBU's Cash from Financing Activities at $2.7 million in Q1 2026, $4.1 million in Q4 2025, and $277000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 17.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.94 Mn |
| Jun 30, 2026 | 17.94 Mn |
| Mar 31, 2026 | 2.70 Mn |
| Mar 31, 2026 | 2.70 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Dec 31, 2025 | 4.07 Mn |
| Sep 30, 2025 | 277,000.00 |
| Sep 30, 2025 | 277,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 3.86 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 244,000.00 |
| Sep 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 132,000.00 |
| Mar 31, 2024 | 12.49 Mn |
| Mar 31, 2024 | 12.49 Mn |